MS News: October 2015


It was a busy month. ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis Congress; October 7 – 10, 2015 in Barcelona) came and went, with insight and data offered on existing and new therapies.

Also, a friend of mine has been in the news after she felt a marked improvement in her walking ability after being prescribed antiretroviral HIV drugs for a 28 day period as a preventative measure after a health scare.

Shoshana spent years in a wheelchair, and as someone who used to love dancing myself, I can only imagine the excitement she felt being able to walk short distances again, albeit with crutches. Needless to say, the antiretroviral drugs did not cure Shoshana, nor did it reverse MS damage to her CNS, but it temporarily helped with some of her symptoms like spasticity. Sadly, three days after Shoshana finished taking the medication, its effects had worn off and her level of spasticity had returned to pre-antiretroviral drug intake.

The findings of the small trial examining the possible link between HIV antiretroviral drugs and MS are still unpublished, and longer studies will need to be carried out before it can be used as a safe-bet type of medicine.

Seeing this level of physical improvement however, in someone within my own circle of friends strengthens my belief that within us lies the power and knowledge that we can all be part of the solution. That solution may not be “the cure” (we need to remain realistic in what is pharmaceutically achievable), but it brings us one step closer to a better understanding of viruses and MS.

If you want to read more about Shoshana’s experience, you can do so here, while other media coverage is listed in the Highlight! section.


  1. Multiple sclerosis patient walks after taking HIV drugs
  2. HIV drugs helps multiple sclerosis patient walk again
  3. Woman with multiple sclerosis walks again after taking HIV drug


  1. ECTRIMS 2015 Congress: a Look at Young Investigator Session II
  2. Discovering a New World in MS Through Genomics, ECTRIMS 2015
  3. Gilenya’s Clinical Trial Results Presented at ECTRIMS Reinforce Long-Term Efficacy Profile in …
  4. ECTRIMS Highlights Latest Developments in Multiple Sclerosis Research
  5. EMD Serono To Present New Data on Rebif, a Therapy for RRMS, at Upcoming ECTRIMS Congress
  6. Biogen to Highlight Broad Research Commitment to MS Care at ECTRIMS Congress
  7. Teva Reinforces Focus on Advancing Multiple Sclerosis Treatment at 31st ECTRIMS Congress


  1. Latest research on cognitive dysfunction in Multiple Sclerosis patients an eye opener
  2. Transcranial Direct Current Stimulation Promising for Multiple Sclerosis
  3. ‘Bad’ White Blood Cells Responsible for Multiple Sclerosis
  4. New finding will help target multiple sclerosis immune response
  5. New multiple sclerosis treatment using B cell depletion therapy
  6. Prof. Jorge Correale Reviews Environmental Factors Associated with Multiple Sclerosis at …
  7. Generic Antibiotic May Reduce Progression to Multiple Sclerosis
  8. Weight and sun exposure linked to onset of multiple sclerosis
  9. Sunlight May Delay Onset of Multiple Sclerosis
  10. Cervical Cord Atrophy, Lesions Predict Disability in Multiple Sclerosis
  11. Experimental cancer drug shows therapeutic promise in mouse models of multiple sclerosis
  12. New study removes cancer doubt for multiple sclerosis drug Queen Mary, University of London
  13. Experimental drug shows promise in mice with multiple sclerosis

Clinical trials

  1. The Big Idea: Multiple sclerosis clinical trial shows promise
  2. The Future of Stem Cell Therapy for Multiple Sclerosis Patients Relies on Clinical Trial Participation
  3. In Third Trial, Ocrelizumab Shows Promise in Progressive MS
  4. Similar Effects Seen for Fingolimod, Placebo in Primary Progressive Multiple Sclerosis
  5. Roche Drug Ocrelizumab Proves Effective Against Multiple Sclerosis In Clinical Trials

Medical treatment news

  1. In the news Ocrelizumab excites ECTRIMS
  2. New drug called ‘groundbreaking’ in multiple sclerosis fight
  3. Teva Pharmaceutical Industries’ COPAXONE 40 mg/mL Three-times-a-week Approved in Russia …
  4. Teriflunomide Slows Brain Volume Loss in MS
  5. Teriflunomide Slows Brain Atrophy in Relapsing Multiple Sclerosis
  6. Generic Multiple Sclerosis Drug Found Equivalent To Brand Medication
  7. Genzyme Provides Update on Lemtrada for Patients with Relapsing-Remitting Multiple Sclerosis …
  8. DMF Reduces Disease Activity Long-Term in Multiple Sclerosis
  9. Natalizumab Effective for Pediatric Multiple Sclerosis
  10. Roche drug succeeds in hard-to-treat form of multiple sclerosis
  11. ‘Multiple sclerosis drugs should be offered earlier’
  12. Bayer introduces autoinjector for its multiple sclerosis drug to counter looming generics
  13. Tysabri May be Tx Option in Kids With MS
  14. Could Genentech have a $5 billion blockbuster MS drug?

Holistic treatment news

  1. Medical Marijuana Now Legal in Croatia for Medical Purposes, Including Multiple Sclerosis
  2. Mental Coaching Can Boost Multiple Sclerosis Patients’ Quality of Life
  3. Online Cognitive Behavioral Therapy Reduces Fatigue in Multiple Sclerosis


  1. How diet may affect the progression of multiple sclerosis Ruhr-University Bochum
  2. In multiple sclerosis, dietary fatty acids effect on gut immune system may affect progress
  3. High Intake of Plant-based Fatty Acids May Lower MS Risk
  4. Good Cholesterol Helps Prevent Brain Lesion Formation in Multiple Sclerosis

MS Organisations

  1. True cost of multiple sclerosis revealed


  1. Consortium of Multiple Sclerosis Centers (CMSC) Emphasizes the Role of Physicians in MS …
  2. 3 Female Celebrities Help with Multiple Sclerosis Research
  3. We Must Talk About Multiple Sclerosis More
  4. NEDA-4 More Accurate Measure of Activity in Relapsing Multiple Sclerosis
  5. Smoking Cessation Slows Brain Volume Loss in Multiple Sclerosis

Questions & Answers

  1. Q&A With Maha Radhakrishnan From Biogen: Zinbryta Looks To Bring New Tool to Multiple …
  2. Q&A With Klaus Marten From Bayer Healthcare: New Autoinjector Aims to Help Patients With …
  3. Q&A With Kate Dawson From Biogen: Tecfidera Continues To Show Positive Results For Multiple …
  4. Q&A With Deborah Miller From Cleveland Clinic: Measuring Quality of Life Issues In Patients With …
  5. EXCLUSIVE: Top MS Researcher Gives Interview With MS News Today

Business news

  1. Primary Progressive Multiple Sclerosis (PPMS) Therapeutic Pipeline Review, H2 2015
  2. Roche hits multiple sclerosis landmarks
  3. Multiple Sclerosis Market Therapeutics Worth $20 Billion by 2024
  4. Premarket Biotech Digest: Understanding Multiple Sclerosis, Gilead’s Hep C Sales, AstraZeneca …
  5. EMD Serono Announces Publication of PRISMS-15 Years Follow-up Study Results on Rebif for …
  6. Therapy Focus- The Next Multiple Sclerosis Battleground

© Willeke Van Eeckhoutte and Ireland, Multiple Sclerosis & Me, 2011-2015. Unauthorized use and/or duplication of this material without express and written permission from this blog’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Willeke Van Eeckhoutte and Ireland, Multiple Sclerosis & Me with appropriate and specific direction to the original content.

Your thoughts?

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.